Clinical efficacy of locally advanced breast cancer treated with docetaxel and doxorubicin / 中国生化药物杂志

ABSTRACT

Objective To evaluate the specific methods and clinical efficacy of docetaxel combined with doxorubicin in the treatment of locally advanced breast cancer and to evaluate its safety.MethodsThe clinical data of 72 pitients with locally advanced breast cancer who were treated in our hospital from July 2012 to July 2016 were retrospectively analyzed.According to the random double blind method,the patients were divided into the control group and the experimental group,with 36 cases in each group.The control group were treated with cyclophosphamide,5-fluorouracil and ammonia armor pterin methotrexate treatment,the experimental group were treated with docetaxel combined with adriamycin treatment,21 days for a cycle,withThe clinical curative effect,toxicity and quality of life were compared between the two groups of patients two cycles of treatment after the completion of the assessment.Results The total remission rate of the experimental group was 75.0％,which was significantly higher than that in control group 41.7％(P<0.05); the main adverse reactions were gastrointestinal reaction and bone marrow suppression,two groups of patients with 0-I,nausea and vomiting,hair loss,diarrhea,fatigue,white blood cell reduction,blood loss,blood loss,heart rate disorders,abnormal liver function and peripheral phlebitis.Two groups were compared.The two groups had no significant difference.Conclusion Docetaxel combined with adriamycin in the treatment of locally advanced breast cancer had definite and toxic and side reaction were slightly in patients can tolerance range,to promote the rehabilitation of patients,improve the quality of life has a very positive significance for popularization and application in the medical practice.